SEngine Precision Medicine
SEngine Precision Medicine innovatively engineers next-gen cancer-targeted drugs.
Founded
2015SEngine Precision Medicine innovatively engineers next-gen cancer-targeted drugs.
Founded with the mission to revolutionize cancer treatment, SEngine Precision Medicine leverages cutting-edge 3D organoid technology and proprietary algorithms to develop next-generation cancer-targeted drugs. The company focuses on providing personalized treatment options by testing numerous cancer drugs against a patient's unique tumor organoid outside the body. This innovative approach aims to empower patients and oncologists with more informed and effective treatment options, ultimately improving patient outcomes and transforming cancer care.
SEngine Precision Medicine has garnered attention from notable investors and industry leaders in the biotech and pharmaceutical sectors. The company's high-throughput technology has led to significant advancements in personalized medicine, earning recognition for its potential to accelerate drug development and improve treatment efficacy. Through its pioneering work, SEngine has made a substantial impact on the field of oncology, offering hope for more precise and effective cancer treatments.
Companies similar to SEngine Precision Medicine include OncoPrecision, Ariz Precision Medicine, ChemoSen3D and D2G Oncology.
SEngine Precision Medicine was founded in 2015.
SEngine Precision Medicine's headquarters is located in Seattle, WA, US.
SEngine Precision Medicine's most recent funding round was for $10M (USD) in July 2022.
As of Jul 28, 2022, SEngine Precision Medicine has disclosed funding of $21.2M (USD). Undisclosed round amounts are excluded.
SEngine Precision Medicine has 23 employees as of Feb 5, 2024.
D2G Oncology
d2g-oncology.com
